コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 Castleman disease (CD) in the context of human immunodef
2 Castleman disease (CD) is a lymphoproliferative disorder
3 Castleman disease can occur in association with autoimmu
4 Castleman disease was initially described over 50 years
5 Castleman disease, an unusual condition of unknown cause
6 Castleman's disease is a rare primary disease of the lym
10 less commonly primary effusion lymphoma and Castleman's disease; these neoplastic diseases are repor
13 si's sarcoma, primary effusion lymphoma, and Castleman's disease are the major malignancies associate
14 si's sarcoma, primary effusion lymphoma, and Castleman's disease, encodes several pathogenically impo
17 herapies successful in the treatment of both Castleman disease and associated autoimmune disease.
20 ganomegaly, potentially including coexisting Castleman disease, endocrinopathy, monoclonal plasma cel
21 tic pemphigus (including 10 with concomitant Castleman's disease) nor from 19 patients with pemphigus
22 Inclusion criteria were pathology-confirmed Castleman's disease in multiple nodes and minimum clinic
23 nd at least 1 of the other 3 major criteria (Castleman disease, sclerotic bone lesions, or elevated V
28 ng of pathogenic cell types and cytokines in Castleman disease have allowed the development of target
29 from January, 1995, with keywords including "Castleman's disease" and "giant lymph node hyperplasia".
30 ) are associated with Kaposi's sarcoma (KS), Castleman's disease, and body cavity-based lymphomas (BC
31 V-8) and its etiologic associations with KS, Castleman's disease, and primary effusion lymphomas.
32 ional criteria were included: a bone lesion, Castleman disease, organomegaly (or lymphadenopathy), en
43 gent of Kaposi sarcoma (KS) and multicentric Castleman disease (MCD), a life-threatening, virally ind
54 phoma (PEL) cell lines, PEL and multicentric Castleman's disease (MCD) tumors, Kaposi's sarcoma lesio
55 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD), all of which are viewed as cy
56 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD), three diseases that frequentl
64 ry effusion lymphoma (PEL), and multicentric Castleman's disease through autocrine or paracrine mecha
65 lopment of Kaposi's sarcoma and multicentric Castleman's disease, as well as a rare form of B cell ly
66 h primary effusion lymphoma and multicentric Castleman's disease, as well as its namesake Kaposi's sa
98 primary effusion lymphoma, and multicentric Castleman's disease; in all of these diseases, interleuk
99 ated with both malignancies and multicentric Castleman's disease; the latter is a rare angiolymphopro
101 ful treatment of HIV-associated multicentric Castleman disease (HIV+MCD) with rituximab-based approac
104 oma (KS) herpesvirus-associated multicentric Castleman disease (KSHV-MCD) is a lymphoproliferative di
105 a herpesvirus (KSHV)-associated multicentric Castleman disease (KSHV-MCD) is characterized by severe
106 recognition of KSHV-associated multicentric Castleman disease (MCD) as a distinct lymphoproliferativ
107 a herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a lymphoproliferative disorde
108 a herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a lymphoproliferative inflamm
109 a herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a polyclonal B-cell lymphopro
111 aposi sarcoma, HHV-8-associated multicentric Castleman disease with microlymphomas and a severe hemop
114 ted in KSHV-positive cells from multicentric Castleman's disease (MCD) and Kaposi's sarcoma (KS) lesi
115 of 128 patients with idiopathic multicentric Castleman's disease had a diagnosis of a separate malign
116 -line treatments for idiopathic multicentric Castleman's disease included corticosteroids (47/128 [37
117 Clinical features of idiopathic multicentric Castleman's disease included multicentric lymphadenopath
118 128 patients with idiopathic multicentric Castleman's disease met all inclusion criteria for the s
119 ed information about idiopathic multicentric Castleman's disease represents a major challenge for cli
120 or 127 patients with idiopathic multicentric Castleman's disease were presented from clinical trials,
121 ent, and outcomes of idiopathic multicentric Castleman's disease, which accounts for at least 33% of
125 (UCD) or the dominant focus in multicentric Castleman's disease (MCD), nature of the surgical approa
126 ted with human herpesvirus-8 in multicentric Castleman's disease support lytic replication, so that c
127 K1 was readily detected in multicentric Castleman's disease tissues, whereas it was not detected
131 inked to Kaposi's sarcoma (KS), multicentric Castleman's disease (MCD), and primary effusion lymphoma
132 ncluding Kaposi's sarcoma (KS), multicentric Castleman's disease (MCD), and primary effusion lymphoma
133 found in Kaposi's sarcoma (KS), multicentric Castleman's disease, and primary effusion lymphomas.
134 vestigated in patients with KS, multicentric Castleman disease (MCD), and primary effusion lymphoma.
136 3%) patients with HHV8-negative multicentric Castleman's disease from 1923 cases of multicentric Cast
137 The cause of HHV8-negative multicentric Castleman's disease is idiopathic; such cases are called
138 plasia to monoclonal neoplasia: multicentric Castleman's disease (CD), Kaposi's sarcoma (KS), and pri
139 reported as a heralding sign of multicentric Castleman disease (MCD) and other lymphoproliferative di
151 effusion lymphoma (PEL) and/or multicentric Castleman disease (MCD), and in 18 (60.0%) of 30 HIV(+),
152 er primary effusion lymphoma or multicentric Castleman disease B-cell malignancies, and from polyclon
154 rimary effusion lymphoma (PEL), multicentric Castleman disease (MCD), and MCD-associated plasmablasti
155 rimary effusion lymphoma (PEL), multicentric Castleman's disease (MCD), and the inflammation-driven n
156 tuximab in posttrans-plantation multicentric Castleman disease patients and non-neoplastic HHV8-assoc
157 HIV-associated plasmablastic multicentric Castleman disease is an increasingly frequent diagnosis.
160 tent lymphadenopathy resembling multicentric Castleman disease in rhesus macaques (RMs) coinfected wi
161 ogic agent of Kaposi's sarcoma, multicentric Castleman's disease, and AIDS-associated primary effusio
162 e for patients with symptomatic multicentric Castleman's disease and well tolerated with prolonged ex
164 ive agent of two B cell tumors, multicentric Castleman disease (MCD) and primary effusion lymphoma (P
165 etiologic agent for KS tumors, multicentric Castleman's disease, and primary effusion lymphomas.
169 ces in understanding the biological basis of Castleman disease have provided new targets for therapeu
172 systematic review of 404 published cases of Castleman's disease to identify the role of the surgeon
177 This review focuses on the intersection of Castleman disease and autoimmunity with an emphasis on s
179 enesis, both involved in the pathogenesis of Castleman disease, may provide additional unique therape
182 Rational approaches to the treatment of Castleman disease have begun to have an impact on diseas
183 ling the multicentric plasma cell variant of Castleman's disease, characterized by persistent angiofo
184 there is mild FDG localization within pelvic Castleman's disease with standard uptake values lower th
185 ma-herpesvirus that causes Kaposi's sarcoma, Castleman's disease and primary effusion lymphomas in tr
187 cal location of the only focus in unicentric Castleman's disease (UCD) or the dominant focus in multi
188 hieving long-term remission in patients with Castleman disease and associated autoimmune features.
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。